COMP <GO>
BVS vs JNJ // EV/EBITDA & P/E VALUATION
Bioventus Inc. (Class A) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BVS 2
— JNJ 10
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $14.87 (+1.50%) • MKT CAP: $1.25B
valuation
26.3x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 67.90% | +0.40 | BVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.40% | 25.50% | -15.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 26.3x | 18.5x | +7.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | 2.97% | +2.80 | BVS | /fcf-yield <GO> |
| Operating Margin | 9.50% | 34.70% | -25.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 4.00% | 28.50% | -24.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 6.00% | -6.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 5.59 | -3.34 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.9 | 62.1 | -18.16 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | 23.0x | +28.20 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.25B | $662.49B | -$661.24B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | JNJ REV | BVS GROSS % | JNJ GROSS % | BVS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $94.19B | 68.3% | 67.9% | $72.1M | $19.70B |
| FY 2024 | $573.3M | $88.82B | 67.7% | 69.1% | $37.8M | $19.84B |
| FY 2023 | $512.3M | $85.16B | — | — | $15.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
JNJ // BETA 1.08